PTC Therapeutics Q1 Earnings Call Highlights

PTC Therapeutics NASDAQ: PTCT reported a record first quarter for product revenue and raised its 2026 revenue outlook, citing strong early demand for Sephience, its treatment for phenylketonuria, or PKU.